A Cuproptosis Nanoparticle Reverses Lung Adenocarcinoma Drug Resistance
Exploration · 10.11.2026
DOI: 10.1002/exp2.70250 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration, online erschienen am 10.11.2026. Verfasst von Leilei Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery Shanghai Pulmonary Hospital School of Medicine Tongji University Shanghai P. R. China. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Residual tumors that received targeted therapy often evolve into drug resistance, with an increasing risk of recurrence and metastasis. By analyzing patient data, it is found that KRAS ‐mutated lung adenocarcinoma (LUAD) exhibits a worse survival rate than wild‐type LUAD. Although the clinical drug AMG‐510 has been approved to treat KRAS(G12C) ‐mutated LUAD, its effectiveness is still limited by drug resistance. Cuproptosis, a newly identified mode of cellular death, shows promise in cancer treatment and in reversing drug resistance. By comparing cell lines with different sensitivities to AMG‐510, we discovered that ATP7B , a key regulator of cuproptosis, was up‐regulated in AMG‐510‐resistant cell lines to decrease their sensitivity to cuproptosis. Therefore, a targeted sensitization strategy focused on cuproptosis was proposed using a single nanoparticle based on bovine serum albumin encapsulating copper ions (termed CuNPs). Both in vitro and in vivo results demonstrated that these nanoparticles released copper ions in an acidic environment, and the following CuNP‐triggered cuproptosis could effectively down‐regulated ATP7B , which successfully overcame AMG‐510 resistance with a synergistic antitumor effect. Collectively, targeting cuproptosis in KRAS‐mutated lung adenocarcinoma emerges as a compelling strategy to address drug resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery Shanghai Pulmonary Hospital School of Medicine Tongji University Shanghai P. R. China.
- Department of Thoracic Surgery Zhejiang Cancer Hospital Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences Hangzhou P. R. China.
- Department of Orthopaedics Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases Shanghai Institute of Traumatology and Orthopaedics Ruijin Hospital Shanghai Jiao Tong University School of Medi…
- Department of Thoracic Surgery and Minimally Invasive Thoracic Surgery Unit Coruña University Hospital Coruña Spain.
- Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences Suzhou P. R. China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Wu, L., Li, K., Wang, H., Ma, S., Wang, R., Fan, Y., Qin, X., Li, M., Gonzalez-Rivas, D., Ji, X., Ni, D., & Xie, D. (2026). A Cuproptosis Nanoparticle Reverses Lung Adenocarcinoma Drug Resistance. Exploration. https://doi.org/10.1002/exp2.70250
Vancouver
Wu L, Li K, Wang H, Ma S, Wang R, Fan Y, et al. A Cuproptosis Nanoparticle Reverses Lung Adenocarcinoma Drug Resistance. Exploration. 2026. doi:10.1002/exp2.70250
BibTeX
@article{Wu2026,
author = {Wu, Leilei and Li, Kun and Wang, Han and Ma, Shangshang and Wang, Rangrang and Fan, Yongfei and Qin, Xichun and Li, Mingjun and Gonzalez-Rivas, Diego and Ji, Xiuru and Ni, Dalong and Xie, Dong},
title = {A Cuproptosis Nanoparticle Reverses Lung Adenocarcinoma Drug Resistance},
journal = {Exploration},
year = {2026},
doi = {10.1002/exp2.70250}
}
EUVIMED